Hims Stock Heads to $45 as NVO Deal and Legal Settlement Clears GLP-1 Expansion Path

Quick overview

Shares of Hims & Hers Health surged this week after a major legal settlement and partnership with Novo Nordisk strengthened confidence in the company’s strategy to dominate the rapidly expanding weight-loss drug market.

HIMS Stock Posts Massive Weekly Rally

Hims & Hers shares finished higher on Wednesday and are up roughly 66% for the week, marking one of the strongest rallies in the company’s history.

The stock began the week near $15.50 and surged to about $26.50 in after-hours trading, fueled by a wave of announcements that boosted investor sentiment around the company’s weight-loss platform and broader telehealth expansion strategy.

The move represents a dramatic turnaround for the stock, which had been under heavy pressure in recent months. Healthcare equities broadly have faced renewed volatility due to regulatory scrutiny, legal disputes, and mixed earnings results across the sector.

HIMS Chart Monthly – Will March’s Candlestick Exceed February’s Candlestick?

At one point, Hims & Hers shares had fallen nearly 80% from their October highs, briefly dropping below $14. However, the sharp rebound from the 50-month simple moving average suggests the possibility of a broader technical trend shift, with March’s monthly candlestick now closing in on February’s large bearish candle.

Novo Nordisk Partnership Ends Legal Overhang

A major catalyst behind the rally was the announcement of a comprehensive legal settlement and strategic partnership between Hims & Hers and Novo Nordisk.

The agreement effectively ends a high-profile patent dispute tied to the telehealth company’s earlier offering of compounded versions of GLP-1 weight-loss drugs.

Rather than continuing a prolonged legal battle, the companies reached a deal that significantly reshapes their relationship and the competitive dynamics of the fast-growing obesity treatment market.

Under the agreement, Hims & Hers will stop promoting compounded semaglutide products, which had been a central issue in the patent dispute. In exchange, Novo Nordisk granted the company authorization to sell branded versions of its blockbuster medications Ozempic and Wegovy through the HIMS platform.

Strategic Shift Toward Branded GLP-1 Treatments

The partnership represents a major strategic pivot for Hims & Hers.

Previously, the company had drawn criticism for selling compounded alternatives to popular GLP-1 drugs, which some critics argued skirted pharmaceutical intellectual property protections.

Now, by transitioning to an authorized distributor of branded treatments, Hims & Hers has effectively removed the regulatory uncertainty that had weighed on the company’s outlook.

The agreement allows the telehealth platform to sell both injectable and newly released oral versions of Novo Nordisk’s medications directly to consumers through its digital ecosystem.

This shift positions Hims & Hers as a central distribution channel for weight-loss therapies, combining pharmaceutical products with telehealth consultations, prescription services, and subscription-based care.

Lower Drug Prices Expand the Market

Another key element of the partnership is Novo Nordisk’s revised self-pay pricing structure for its GLP-1 medications.

The company recently reduced prices for certain patients to between $149 and $299 per month, significantly improving accessibility for individuals without insurance coverage.

By integrating these medications directly into its platform, Hims & Hers can provide a streamlined experience for patients seeking weight-loss treatment.

The company’s digital interface, subscription services, and nationwide telehealth network create a direct-to-consumer pipeline that could dramatically expand adoption of GLP-1 therapies.

As demand for obesity treatments continues to grow worldwide, this model could position Hims & Hers as one of the dominant online gateways for metabolic health management.

Analysts Turn More Bullish

The market reaction to the deal was swift and powerful. When news of the partnership first broke, Hims & Hers shares surged more than 36% in pre-market trading, triggering a sustained rally throughout the week.

Several major Wall Street firms responded by upgrading the stock. Analysts at institutions including Bank of America and Citi shifted their ratings from Hold to Buy, citing the elimination of legal risk and the significant expansion of the company’s total addressable market.

Investors now view the company not merely as a telehealth provider but as a major distribution platform for next-generation weight-loss treatments.

A Potential Turning Point for Hims & Hers

While risks remain—including regulatory oversight and competition within the rapidly evolving telehealth and obesity treatment industries—the partnership with Novo Nordisk marks a potential turning point for the company.

By resolving its legal conflict and aligning itself with one of the world’s largest pharmaceutical companies, Hims & Hers has strengthened its credibility in the healthcare ecosystem.

If demand for GLP-1 medications continues to surge, the company’s integrated digital platform could become a key gateway connecting patients, doctors, and pharmaceutical treatments in the rapidly expanding metabolic health market.

ABOUT THE AUTHOR See More

Skerdian Meta

Lead Analyst

Skerdian Meta Lead Analyst. Skerdian is a professional Forex trader and a market analyst. He has been actively engaged in market analysis for the past 11 years. Before becoming our head analyst, Skerdian served as a trader and market analyst in Saxo Bank's local branch, Aksioner. Skerdian specialized in experimenting with developing models and hands-on trading. Skerdian has a masters degree in finance and investment.